Sep. 10 at 1:48 PM
$NVCR Wells Fargo 21st Annual Healthcare Conference
Chief Executive Frank Leonard said the company is seeing strong early demand for Optune Pax in pancreatic cancer, continued growth in glioblastoma and early momentum in Japan, even as it works through payer coverage, a new rival therapy and a cybersecurity incident.
Key Takeaways
NovoCure said second-quarter 2026 was the first time in several years that it generated positive cash flow.
Optune Pax produced about 600 prescriptions in roughly four months and had about 285 active patients on therapy at quarter-end.
Optune Gio, the company’s glioblastoma franchise, posted 11% active-patient growth in the quarter, with 8% growth in the U.S.
Japan is becoming a larger growth driver, with Optune Lua already on the market and Optune Pax expected to gain approval by year-end 2026.
Management said it is keeping spending disciplined, with annual R&D around
$200 million and no step-up expected in sales and marketing.
